Clinical trials: Cognition
Mild to Moderate Alzheimer Disease, Cognitive Impairment
An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease
The primary purpose of this study is to determine the efficacy and safety of Sodium Oligo-mannurarate (GV-971) in 36-week treatment of mild to moderate Alzheimer's disease.
- Trial name
- NCT02293915
- Testing
- Sodium oligo-mannurarate 900mg
- Where
- 16 sites in China
- Volunteers
- 818 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Alzheimers Disease
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
- Trial name
- TRONTIER 1 (NCT07169578)
- Testing
- Trontinemab
- Where
- 142 sites in United States, Argentina and 11 more
- Volunteers
- 1,101 people
- Sponsor
- Hoffmann-La Roche
MCI, Mild Cognitive Impairment
The Interactive Physical and Cognitive Exercise System (v3) for Mild Cognitive Impairment (MCI)
The primary purpose of this study is to attempt to replicate and extend promising pilot findings regarding the cognitive benefits of in-home neuro-exergaming with iPACES (interactive Physical and Cognitive Exercise System v3) for…
- Conditions
- MCI, Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- iPACES (NCT05009524)
- Testing
- iPACES (interactive Physical and Cognitive Exercise System), PACE (Physical and Cognitive Exercise)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- iPACES LLC
Insulin Resistance, Obesity
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity
A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments.
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment
- Trial name
- NCT06242535
- Testing
- GLY-LOW
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Health Services Accessibility, Rural Health
Health Ahead Comparative Effectiveness Study
The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening on the path toward a fully automated screening…
- Conditions
- Health Services Accessibility, Rural Health, Medically Underserved Area, Preventive Health Services
- Trial name
- HACE (NCT07669168)
- Testing
- AI-Assisted Screening Interpretation (AI Reads), Human-Only Screening Interpretation
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- William Brandenburg, MD
Alzheimer's Disease
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of…
- Trial name
- MissionAD1 (NCT02956486)
- Testing
- Elenbecestat
- Where
- 258 sites in United States, Argentina and 16 more
- Volunteers
- 2,212 people
- Sponsor
- Eisai Co., Ltd.
Healthy Volunteers
Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
- Trial name
- NCT00170768
- Testing
- Darifenacin, Oxybutynin
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Novartis
Cognitive Dysfunction
Association Between qEEG Measure and Post-Operative Cognitive Dysfunction (POCD) and Postoperative Delirium (POD)
Cognitive complications after major surgery are a common phenomenon. The incidence of Postoperative Cognitive Dysfunction (POCD), may vary from 5% to 25% in adult patients, depending on different risk factors.
- Trial name
- NCT03977350
- Testing
- EEG monitoring
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Neuroindex Ltd.
Fall, Mild Cognitive Impairment (MCI)
Digital STEADI Efficacy
The aging of the U.S. population, combined with health care workforce shortages and insufficient access to effective fall prevention and exercise programs, has contributed to a high burden of fall-related injuries in older…
- Conditions
- Fall, Mild Cognitive Impairment (MCI), Aging
- Trial name
- NCT07852650
- Testing
- Digital STEADI-1, STEADI Standard of Care, Digital STEADI-2
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Friendi.fi Corporation
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depression
Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls
The purpose of this study is to determine if Vortioxetine 20 mg/day will lead to changes in neural activity (BOLD signal), as measured using fMRI, in brain areas associated with executive functioning and memory during cognitive…
- Trial name
- NCT01607125
- Testing
- Vortioxetine (Lu AA21004)
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder, MDD
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
Xanamem is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Major Depressive Disorder, MDD, Cognitive Impairment
- Trial name
- NCT05657691
- Testing
- Xanamem™
- Where
- 12 sites in Australia, United Kingdom
- Volunteers
- 167 people
- Sponsor
- Actinogen Medical
Major Depressive Disorder
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
This study aims at evaluating the effect of vortioxetine on cognitive dysfunction in major depressive disorder (MDD) patients with inadequate response to current antidepressant treatment.
- Trial name
- NCT02272517
- Testing
- Vortioxetine 10-20 mg, Escitalopram 10-20 mg
- Where
- 16 sites in Finland, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Dementia Alzheimer's Type
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Primary Objective: To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's disease (AD) while on…
- Trial name
- NCT01266525
- Testing
- SAR110894, Donepezil
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 291 people
- Sponsor
- Sanofi
Neurocognitive Disorders, Mild, Cognitive Impairment, Mild
Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such…
- Conditions
- Neurocognitive Disorders, Mild, Cognitive Impairment, Mild, Depression Mild, Apathy
- Trial name
- NCT07237009
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- KompanionCare SAS
Moderate Acute Malnutrition
Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old
The aim of this open-label randomized controlled trial conducted in four African countries (Madagascar, Niger, Central African Republic and Senegal) is to compare three strategies of renutrition for moderate acute malnutrition…
- Trial name
- MALINEA (NCT03474276)
- Testing
- Azythromycin, Inuline and fructo-oligosaccharides, Albendazole
- Where
- 4 sites in Central African Republic, Madagascar and 2 more
- Volunteers
- 1,357 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI)
Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease
The goal of this study is to learn if medical image analysis software, Neurophet SCALE PET, can enhance readers' amyloid beta positivity performance in people with Alzheimer's Disease.
- Trial name
- NCT07417540
- Testing
- Neurophet SCALE PET
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- NEUROPHET
Cognitive Function
Nutrilite Memory Builder on the Improvement of Cognitive Function
Its a randomized controlled trial, to evaluate the effect of NUTRILITE Memory Builder on the improvement of cognitive function in middle-aged and elderly people.
- Trial name
- NCT05591885
- Testing
- Study product group (Nutrilite Memory Builder)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Amway (China) R&D Center